Curi RMB Capital LLC Sells 347,136 Shares of Edwards Lifesciences Co. (NYSE:EW)

Curi RMB Capital LLC reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 93.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,295 shares of the medical research company’s stock after selling 347,136 shares during the quarter. Curi RMB Capital LLC’s holdings in Edwards Lifesciences were worth $1,537,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of EW. Crewe Advisors LLC bought a new stake in Edwards Lifesciences in the first quarter valued at $28,000. First Community Trust NA bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $29,000. Webster Bank N. A. acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $39,000. Peoples Bank KS bought a new position in Edwards Lifesciences during the 3rd quarter valued at about $40,000. Finally, Versant Capital Management Inc lifted its holdings in Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 326 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on EW. Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Wells Fargo & Company cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. The Goldman Sachs Group lowered their price target on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Royal Bank of Canada cut their price objective on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Trading Up 2.4 %

EW opened at $67.76 on Friday. The firm’s fifty day simple moving average is $67.42 and its 200 day simple moving average is $76.37. The stock has a market capitalization of $39.96 billion, a P/E ratio of 9.78, a P/E/G ratio of 3.74 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 earnings per share. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 4.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,250 shares of company stock valued at $2,744,438 over the last 90 days. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.